vTv Therapeutics Drops as Diabetes Study Date Approaches
vTv Therapeutics Inc. shares fell 1.1% to $33.14 Friday afternoon, lagging behind a stronger biotech market with investors waiting on further news from its diabetes program. The SPDR S&P Biotech ETF gained around 0.8%, and the iShares Nasdaq Biotechnology ETF was up 0.2%. vTv shares are trading now mostly on prospects for cadisegliatin, its oral candidate being trialed as an add-on to insulin in type 1 diabetes. The company said in a May 13 update that it still expects to finish enrolling its Phase 3 CATT1 study in the third quarter of 2026.